TG‐1701, A SELECTIVE BRUTON TYROSINE KINASE (BTK) INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH UBLITUXIMAB AND UMBRALISIB (U2) IN PATIENTS WITH B‐CELL MALIGNANCIES
Autor: | Stanley Cheung, H.P. Miskin, Tomasz Wróbel, Owen A. O'Connor, Krzysztof Giannopoulos, Wojciech Jurczak, C. K Yannakou, C.Y. Cheah, A. D Ricart, Nicholas Wickham, J. P. Tang, M. Lasica, Katharine L Lewis, Jan Walewski, Constantine S. Tam, E. Normant, M. Długosz-Danecka |
---|---|
Rok vydání: | 2021 |
Předmět: |
Cancer Research
medicine.medical_specialty biology business.industry Atrial fibrillation Hematology General Medicine medicine.disease Gastroenterology Discontinuation Oncology Refractory Chemoimmunotherapy Internal medicine Cohort Toxicity medicine biology.protein Bruton's tyrosine kinase Adverse effect business |
Zdroj: | Hematological Oncology. 39 |
ISSN: | 1099-1069 0278-0232 |
Popis: | Introduction: TG-1701 is a selective, covalent BTK inhibitor administered once daily (QD). Both the “U2” combination (anti-CD20 mAb ublituximab + the PI3Kδ-CK1ϵ inhibitor umbralisib) and BTK inhibition are highly active in treatment-naive (TN) and relapsed/ refractory (R/R) CLL, each having previously demonstrated superiority over standard chemoimmunotherapy. Herein we report the results of the dose escalation of TG-1701 monotherapy and TG-1701+U2. Methods: Patients (pts) with R/R CLL, MCL and Waldenstrom's (WM) were enrolled in an ongoing Ph 1 study initially evaluating dose escalation (DE) of oral TG-1701 QD continuously administered in 28-day cycles (100, 200, 300, and 400 mg). After characterizing the safety profile of TG-1701 monotherapy, we implemented a parallel DE arm of TG-1701+U2. Select dose levels of TG-1701 monotherapy were expanded. All pts were treated until disease progression, unacceptable toxicity, or investigator/patient decision to withdraw. Results: As of 03 February 2021, 123 pts were treated with TG-1701 as follows: 25 in the monotherapy DE arm, 61 in the 200 mg disease-specific cohorts (20 CLL [5 TN], 21 MCL [4 TN], 20 WM [8 TN]), 20 in the 300 mg CLL cohort (4 TN), and 17 in the 1701+U2 DE arm. The median # of prior therapies was 1 (range, 1-10). All pts were BTKi-naive. All 123 pts were evaluable for safety. TG-1701 was well tolerated and the maximum tolerated dose (MTD) for monotherapy was not reached at 400 mg (demonstrating near 100% saturation of the BTK at all dose levels studied). Treatment emergent adverse events (TEAE) of clinical interest included atrial fibrillation (AF 4.0% of pts, G ≥3 in 1 case), G ≥3 hypertension (2.4%), and bleeding events (18.7%, all G1-2). No cases of ventricular tachyarrhythmia were reported. TEAEs leading to TG-1701 dose reduction occurred in 6.5% of pts. TEAEs leading to treatment discontinuation occurred in 1.6% of pts (AF, COVID-19). At the data cut-off, 119 pts were evaluable for response, including 40 in DE (Table). The median duration of response has not been reached among responders overall. The median follow-up (mFU range) was 15.9 mos (1.3-28.6+) in DE and 8.5 mos (1.4-15.6+) in disease-specific cohorts. Best change from baseline in tumor burden in pts in the 1701+U2 combination arm is presented in the figure below. Conclusions: TG-1701 exhibits an encouraging safety and efficacy profile. The combination of 1701+U2 has been well tolerated and dose escalation continues. The combination shows enhanced depth of response over TG-1701 monotherapy. |
Databáze: | OpenAIRE |
Externí odkaz: |